Patents by Inventor Krzysztof Palczewski

Krzysztof Palczewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100135977
    Abstract: A pharmaceutical composition for treating a metabolic disease in a mammalian subject includes a therapeutically effective amount of all-trans-13,14-dihydroretinoid, all-trans-13,14-dihydroretinoid derivative, or agent capable of modulating the level of at least one all-trans-13,14-dihydroretinoid or all-trans-13,14-dihydroretinoid derivative in the subject.
    Type: Application
    Filed: October 9, 2007
    Publication date: June 3, 2010
    Inventors: Krzysztof Palczewski, Radu A. Moise
  • Patent number: 7706863
    Abstract: In one aspect the present invention provides methods for assessing a physiological state of a mammalian retina in vivo, the methods of this aspect of the invention each include the steps of: (a) irradiating a portion of a mammalian retina, in vivo, with light having a wavelength in the range of from 600 nm to 1000 nm at an intensity sufficient to stimulate two-photon-induced fluorescence in the retina; and (b) assessing a physiological state of the retina by analyzing the fluorescence.
    Type: Grant
    Filed: August 26, 2004
    Date of Patent: April 27, 2010
    Assignee: University of Washington
    Inventors: Yoshikazu Imanishi, Krzysztof Palczewski, Bryan S. Sires, Eric J. Seibel
  • Publication number: 20100035986
    Abstract: A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C1-C10 monocarboxylic acids and C2-C22 polycarboxylic acids.
    Type: Application
    Filed: February 10, 2009
    Publication date: February 11, 2010
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Tadao Maeda, David Saperstein, Krzysztof Palczewski
  • Publication number: 20090253589
    Abstract: In one aspect the invention relates to a method for testing a chemical entity for its capability to modulate a (poly)peptide that is malfunctioning by means of an interaction of said chemical entity and said (poly)peptide, the method using single-molecule force spectroscopy. In another aspect the invention relates to a method for testing a chemical or physical entity for its capability to interact with a G protein-coupled receptor (GPCR) in its natural membrane environment, the method using single-molecule force spectroscopy.
    Type: Application
    Filed: September 5, 2006
    Publication date: October 8, 2009
    Applicant: Nambition GmbH
    Inventors: Daniel Müller, Tanuj Sanpra, Krzysztof Palczewski, Paul Shin-Hyun Park
  • Publication number: 20080275134
    Abstract: A method is provided for treating a degenerative disease in a vertebrate eye. A method is further provided for preventing photoreceptor degeneration in a vertebrate eye.
    Type: Application
    Filed: February 24, 2006
    Publication date: November 6, 2008
    Applicant: University of Washington
    Inventors: Krzysztof Palczewski, Marcin Golczak, Vladimir Kuksa
  • Publication number: 20080249042
    Abstract: Compositions of all-trans-retinol: all-trans-13,14-dihydroretinal saturase and methods of use thereof are provided.
    Type: Application
    Filed: September 9, 2005
    Publication date: October 9, 2008
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Alexander R. Moise, Vladimir A. Kuksa, Krzysztof Palczewski
  • Publication number: 20080221208
    Abstract: Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.
    Type: Application
    Filed: June 20, 2005
    Publication date: September 11, 2008
    Applicant: University of Washington
    Inventors: Krzysztof Palczewski, Matthew Batten
  • Publication number: 20060281821
    Abstract: Compositions of and methods for using synthetic retinoids as retinoid replacements and opsin agonists are provided.
    Type: Application
    Filed: March 15, 2004
    Publication date: December 14, 2006
    Inventors: Krzysztof Palczewski, David Saperstein
  • Publication number: 20060252107
    Abstract: The present invention relates generally to the preparation and use of retinoid N-retinylidene-N-retinyl-ethanolamine (A2E) conjugated to a carrier polypeptide and to the preparation and use of antibodies that bind specifically to A2E. The invention relates to the use of A2E conjugates as immunogens or vaccines and to the use of A2E specific antibodies for treatment of ophthalmic diseases. Provided herein are methods for enhancing retinal neuronal cell survival, including photoreceptor cell survival, using antibodies that specifically bind to A2E or by inducing an immune response using an A2E immunoconjugate. Enhancing survival of photoreceptor cells or decreasing accumulation of A2E in the eye using the A2E immunoconjugates or A2E specific antibodies is useful for treatment of ophthalmic diseases such as macular degeneration.
    Type: Application
    Filed: February 22, 2006
    Publication date: November 9, 2006
    Applicant: Acucela, Inc.
    Inventors: Ryo Kubota, Krzysztof Palczewski, Anna Gall
  • Publication number: 20050159662
    Abstract: In one aspect the present invention provides methods for assessing a physiological state of a mammalian retina in vivo, the methods of this aspect of the invention each include the steps of: (a) irradiating a portion of a mammalian retina, in vivo, with light having a wavelength in the range of from 600 nm to 1000 nm at an intensity sufficient to stimulate two-photon-induced fluorescence in the retina; and (b) assessing a physiological state of the retina by analyzing the fluorescence.
    Type: Application
    Filed: August 26, 2004
    Publication date: July 21, 2005
    Inventors: Yoshikazu Imanishi, Krzysztof Palczewski, Bryan Sires, Eric Seibel
  • Publication number: 20050124792
    Abstract: The invention provides a transgene construct, containing a nucleic acid encoding a photoreceptor specific regulatory sequence, a membrane-associated polypeptide, and a photoreceptor outer segment targeting signal. For example, the invention pro-vides a transgene construct, containing a nucleic acid encoding a rhodopsin promoter, a membrane-associated polypeptide, and a rod outer segment (ROS) targeting signal. In addition, the invention provides a gene targeting construct containing a transgene encoding a polypeptide that contains a rod outer segment (ROS) targeting signal. The transgene is flanked by 5? and 3? DNA sequences that are homologous to the rhodopsin gene. Homologous recombination between the construct and a rhodopsin gene results in operable association between the transgene and a rod-specific regulatory sequence.
    Type: Application
    Filed: November 21, 2002
    Publication date: June 9, 2005
    Inventors: Krzysztof Palczewski, Ning Li, Juan Ballesteros
  • Publication number: 20050091702
    Abstract: The invention provides a transgene construct consisting of a transgene encoding a membrane polypeptide comprising a rod outer segment (ROS) targeting signal, and an operably associated species specific rod-specific regulatory sequence, wherein said polypeptide is not rhodopsin. The membrane polypeptide can be a G protein-coupled receptor (GPCR). Transgenic membrane polypeptides include a receptor selected from 5HT1A, 5HT1B, 5HT1D, 5HT1E, 5HT1F, 5HT2A, 5HT2B, 5HT2C, 5HT4A, 5HT5A, 5HT6, 5HT7A, EDG1, EDG2, EDG3, EDG4, EDG5, EDG6, EDG7, EDG8, CB2, FMLP and MC4. The invention also provides a Xenopus cell whose genome contains a transgene encoding a membrane polypeptide comprising a ROS targeting signal operably associated with a Xenopus rod-specific regulatory sequence, wherein said polypeptide is not a rhodopsin.
    Type: Application
    Filed: April 23, 2004
    Publication date: April 28, 2005
    Inventors: Krzysztof Palczewski, Ning Li, Juan Ballesteros
  • Publication number: 20040244070
    Abstract: The invention provides a gene targeting construct containing a transgene encoding a polypeptide that contains a rod outer segment (ROS) targeting signal. The transgene is flanked by 5′ and 3′ DNA sequences that are homologous to the rhodopsin gene. Homologous recombination between the construct and a rhodopsin gene results in operable association between the transgene and a rod-specific regulatory sequence. The invention also provides cells and animals whose genome contain a functional disruption of one or both endogenous rhodopsin gene alleles, and a transgene encoding a polypeptide that contains a ROS targeting signal operably associated with a rod-specific regulatory sequence. The invention constructs, cell and animals can be used to isolate transgenic polypeptides from the ROS membrane.
    Type: Application
    Filed: April 22, 2004
    Publication date: December 2, 2004
    Applicant: Novasite Pharmaceuticals, Inc.
    Inventors: Krzysztof Palczewski, Ning Li, Juan Ballesteros
  • Publication number: 20040242704
    Abstract: Methods and compositions for stabilizing opsin protein in a vertebrate visual system are provided by administration of opsin-binding synthetic retinoids.
    Type: Application
    Filed: March 15, 2004
    Publication date: December 2, 2004
    Applicants: University of Washington, TechTransfer - Invention Licensing, Regents of the University of Minnesota
    Inventors: Krzysztof Palczewski, Shalesh Kaushal, Vladimir Kuksa, Syed M. Noorwez
  • Publication number: 20030097670
    Abstract: The invention provides a gene targeting construct containing a transgene encoding a polypeptide that contains a rod outer segment (ROS) targeting signal. The transgene is flanked by 5′ and 3′ DNA sequences that are homologous to the rhodopsin gene. Homologous recombination between the construct and a rhodopsin gene results in operable association between the transgene and a rod-specific regulatory sequence. The invention also provides cells and animals whose genome contain a functional disruption of one or both endogenous rhodopsin gene alleles, and a transgene encoding a polypeptide that contains a ROS targeting signal operably associated with a rod-specific regulatory sequence. The invention constructs, cell and animals can be used to isolate transgenic polypeptides from the ROS membrane.
    Type: Application
    Filed: November 21, 2001
    Publication date: May 22, 2003
    Inventors: Krzysztof Palczewski, Ning Li, Juan Ballesteros
  • Publication number: 20020142385
    Abstract: The present invention discloses a three-dimensional structure of bovine rhodopsin.
    Type: Application
    Filed: August 3, 2001
    Publication date: October 3, 2002
    Inventors: Masashi Miyano, Takashi Kumasaka, Tetsuya Hori, Hiroyuki Motoshima, Tetsuji Okada, Masaki Yamamoto, Krzysztof Palczewski, Craig A. Behnke, Brian A. Fox, Isolde Le Trong, David C. Teller, Ronald E. Stenkamp
  • Patent number: 5753522
    Abstract: A composition useful in a method for diagnosing cancer-associated retinopathy including the steps of acquiring a purified aliquot of 26 kDa protein, and, utilizing the protein, or a unique fragment thereof, to perform a patient-serum assay to identify in a sample of a patient's serum the presence of autoantibodies to the 26 kDa protein autoantigen.
    Type: Grant
    Filed: April 10, 1995
    Date of Patent: May 19, 1998
    Assignee: Legacy Good Samaritan Hospital and Medical Center
    Inventors: Arthur S. Polans, Krzysztof Palczewski
  • Patent number: 5405749
    Abstract: A method of screening for cancer-associated retinopathy including the steps of acquiring a purified aliquot of 26 kDa protein, and, utilizing this protein, or peptides derived therefrom, performing a patient-serum assay to identify in a sample of a patient's serum the presence of autoantibodies to the 26 kDa protein autoantigen.
    Type: Grant
    Filed: December 6, 1991
    Date of Patent: April 11, 1995
    Inventors: Arthur S. Polans, Krzysztof Palczewski